Investor Centre

Our pipeline and lead compound SFX-01 is derived from our proprietary Sulforadex® technology.
Stat background
0.90 GBX Volume: 1,756,751 Market Capitalisation (m) £3.85

TheraCryf plc Full Year Results

29 - May - 2024
Current corporate presentation

Notice of AGM

21 - June - 2024
TheraCryf's AGM will take place on Thursday 18th July 2024 at 2.30pm.

TheraCryf plc - Research and Development Update

14 - June - 2024
TheraCryf plc present an update on the Company including current status of R&D projects.

Major Shareholder

Current ShareholderNumber of sharesPercentage holding
J. R. Kight33,100,0007.75%
Rathbones Investment Management Ltd25,789,2466.03%
Octopus Investments21,875,0005.12%
Vulpes Investment Management Pte Ltd20,554,1914.81%
First Equity Limited20,500,0004.80%
Seneca Partners Limited16,301,4563.81%
The number of ordinary shares in issue is 427,346,895 all of which are in public hands. The Company does not hold any shares in Treasury.
Last updated 13 June 2024